In the first year of the project, a large and functional network of experts was created. GAIA aims to improve the quality of outcome data from clinical vaccine trials in pregnant women with a specific focus on the needs and requirements for safety monitoring in LMIC. The GAIA project was formed in response to the call of the World Health Organization for a globally concerted approach to actively monitor the safety of vaccines and immunization in pregnancy programs. Thorough assessment of benefits and risks for the primarily healthy pregnant women and their unborn babies is required. Immunization in pregnancy provides a promising contribution to globally reducing neonatal and under-five childhood mortality and morbidity. 15 World Health Organization, Geneva, Switzerland.14 Public Health Agency of Canada, Ottawa, Canada.13 Monash University, Melbourne, Australia.12 Erasmus University Medical Center, Rotterdam, The Netherlands.